The therapeutic potential of gypenosides for age-related macular degeneration

Tools

Cen, Shuibin and Li, Jianping and Reilly, James and Chen, Jinwei and Jiang, Hui-Rong and Shu, Xinhua (2026) The therapeutic potential of gypenosides for age-related macular degeneration. Frontiers in Nutrition, 13. 1773391. ISSN 2296-861X (https://doi.org/10.3389/fnut.2026.1773391)

[thumbnail of Cen-etal-FN-2026-The-therapeutic-potential-of-gypenosides-for-age-related-macular-degeneration]
Preview
 Text. Filename: Cen-etal-FN-2026-The-therapeutic-potential-of-gypenosides-for-age-related-macular-degeneration.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (757kB)| Preview

Abstract

Age-related macular degeneration (AMD) is a progressive retinal disease considered to be the leading cause of irreversible vision loss among older adults globally. AMD is classified into non-exudative (dry) AMD and neovascular (wet) AMD (Figure 1). Dry AMD is the commonest type, accounting for approximately 90% of cases and is characterized by atrophy of retinal pigment epithelial (RPE) cells and sub-RPE deposits (drusen); wet AMD is the most severe form and is characterized by the growth of abnormal choroidal vessels and leakage of blood and fluid. Current treatments approved by the Food and Drug Administration (FDA) of the United States include anti-vascular endothelial growth factor (VEGF) treatment for wet AMD and anti-complement treatment for dry AMD, respectively. These lifelong intravitreal treatments can cause adverse complications, including ocular hemorrhage, retinal inflammation, retinal detachment, and cataract. Therefore, development of alternative treatments is urgently needed.

ORCID iDs

Cen, Shuibin, Li, Jianping, Reilly, James, Chen, Jinwei, Jiang, Hui-Rong ORCID logoORCID: https://orcid.org/0000-0002-5753-0091 and Shu, Xinhua;
CORE (COnnecting REpositories)